Aelis Farma (XPAR:AELIS) Margin of Safety % (DCF Earnings Based): N/A (As of Jul. 03, 2026)


XPAR:AELIS Aelis Farma SA XPAR:AELIS
33 GF Score
Price €1.05
GF Value €0.98
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Aelis Farma Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Aelis Farma's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

XPAR:AELIS vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Aelis Farma's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aelis Farma Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aelis Farma's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Aelis Farma's Margin of Safety % (DCF Earnings Based) falls into.


XPAR:AELIS
33GF Score
Aelis Farma SA XPAR:AELIS
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Aelis Farma (XPAR:AELIS) Overvalued in 2026?

Based on GuruFocus' analysis, Aelis Farma stock appears to be overvalued. The current stock price of €1.05 is trading 7.1% above its estimated GF Value™ of €0.98. GuruFocus considers Aelis Farma to be Fairly Valued.

Key valuation signals for XPAR:AELIS:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €0.98 vs. price of €1.05 (7.1% above fair value)
  • GF Score™: 33/100 with 4 warning signs

No single metric tells the full story. See the XPAR:AELIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aelis Farma Business Description

Other Exchanges 69O:Germany
Address 2 rue Robert Escarpit, IECB, Pessac, Bordeaux, FRA, 33607
Aelis Farma SA is a biotechnology Company specializing in the research and development of treatment's related to brain diseases. The Company operates in only one business segment: the research and development of pharmaceutical products.
33GF Score

Get the complete analysis for XPAR:AELIS

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.05
Price
€0.98
GF Value